An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores

Focus Consumer Healthcare80 enrolled

Overview

Focus Consumer Healthcare has developed Herpecin L. Herpecin L combines many different ingredients hypothesized to promote quick healing and symptom reduction from cold sores.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Cold Sores

Interventions

Herpecin LOTHER

Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male Female between 18-60 years of age. * Must be in good health with no significant chronic conditions and a BMI under 35. * Must experience regular cold sores or fever blisters * Must agree to avoid daily lip balm or another product designed to alleviate their cold sore (e.g., Abreva or other over-the-counter cold sore products). Exclusion Criteria: * Suffers from pre-existing conditions that would prevent them from adhering to the protocol including chronic conditions such as oncological or psychiatric disorders. * Anyone with known severe allergic reactions. * Unwilling to follow the study protocol. * Currently pregnant, breastfeeding, or wanting to become pregnant for the duration of the study.

Locations (1)

Citruslabs

Santa Monica, California, United States

Outcomes

Primary Outcomes

The primary aim of this research is to understand the changes in cold sore severity.

Cold sore severity will be measured via survey and cold sore severity grading. Symptom severity is rated on a scale of 0 (Not a problem) to 6 (Severe)

Time frame: 12 weeks

Secondary Outcomes

The secondary objective of this trial is to examine differences in cold sore frequency between the two groups.

Cold sore frequency will be measured via a self-reported survey measuring the frequency of cold sore occurrence during the study period compared to baseline.

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.